Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout

 Hims & Hers Health is planning an entry into the Canadian market next year, timing it with the new availability of a generic weight loss drug a month after losing rights to sell Novo Nordisk's branded version.

The digital health and wellness platform said Wednesday that it plans to enter the country in 2026 and offer access to lower-cost treatment options through its digital platform, including the generic weight loss drug semaglutide.

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of illegally selling cheaper copycats of its own weight-loss drug and engaging in deceptive marketing.

The availability of the generic semaglutide means that the virtually identical drug as the branded version can be offered at much lower prices.

The two companies had only two months prior unveiled what they had called a long-term collaboration to directly provide Wegovy to Hims & Hers patients.

The pharmaceutical giant had also said in June that it had concerns about the safety of knockoff versions of Wegovy, and that Hims & Hers' deceptive marketing of such knockoffs put patient safety at risk.

Hims & Hers said in return that Novo Nordisk was trying to pressure it to steer patients to Wegovy regardless of whether it was the best option for patients.

https://www.morningstar.com/news/dow-jones/202507094803/hims-hers-times-pivot-to-canada-with-generic-weight-loss-drug-after-wegovy-fallout-update